CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)
Curis, Inc.
Curis, Inc.
Incyte Corporation
Dren Bio
AVM Biotechnology Inc
Lyell Immunopharma, Inc.
Merck Sharp & Dohme LLC
Bristol-Myers Squibb
Hackensack Meridian Health
Artiva Biotherapeutics, Inc.
AvenCell Therapeutics, Inc.
National Institutes of Health Clinical Center (CC)
University of Iowa
Vironexis Biotherapeutics Inc.
Pfizer
Taiho Oncology, Inc.
Merck Sharp & Dohme LLC
Sellas Life Sciences Group
M.D. Anderson Cancer Center
National Institutes of Health Clinical Center (CC)
Allogene Therapeutics
University of Chicago
ModeX Therapeutics, An OPKO Health Company
Penn State University
Otsuka Pharmaceutical Co., Ltd.
Children's Oncology Group
Ossium Health, Inc.
National Institutes of Health Clinical Center (CC)
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Seattle Children's Hospital
Essen Biotech
The Lymphoma Academic Research Organisation
SymBio Pharmaceuticals
OSE Immunotherapeutics
Australian & New Zealand Children's Haematology/Oncology Group
National Cancer Institute (NCI)
Dana-Farber Cancer Institute
Sheba Medical Center
M.D. Anderson Cancer Center
Aileron Therapeutics, Inc.
Hanx Biopharmaceuticals (Wuhan) Co., Ltd.
NuCana plc
Evopoint Biosciences Inc.
UNC Lineberger Comprehensive Cancer Center
UNC Lineberger Comprehensive Cancer Center
Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Chinese PLA General Hospital
The Second Hospital of Anhui Medical University
Masonic Cancer Center, University of Minnesota
Dana-Farber Cancer Institute
Institute of Hematology & Blood Diseases Hospital, China